The Medical Letter - 2011
Search or Select Article Below and Click to Purchase
Year:    Publication:      2011 Annual Index: U.S. English | Canadian English
January 10, 2011 (Issue 1355)  
  • In Brief: Non-Inferiority Trials
    Several Medical Letter readers have asked about the meaning of non-inferiority trials. A non-inferiority trial is a comparison with an active control to determine whether the difference in response...
  • Antiviral Drugs for Influenza
    Superseded by The Medical Letter "Antiviral Drugs for Treatment and Prophylaxis of Seasonal Influenza" - Issue 1563, January 14, 2019Antiviral drugs can be used for treatment of patients with...
  • Ella: A New Emergency Contraceptive
    The FDA has approved the use of ulipristal acetate (ella – Watson) as an emergency contraceptive that can be taken up to 5 days after unprotected intercourse. It is available only by...
  • In Brief: Glycopyrrolate Oral Solution for Sialorrhea
    Glycopyrrolate (Robinul, and others), a synthetic muscarinic receptor antagonist, has been used off-label for many years for treatment of excessive drooling in patients with Parkinson’s...
January 24, 2011 (Issue 1356)  
  • Ceftaroline Fosamil (Teflaro) - A New IV Cephalosporin
    The FDA has approved ceftaroline fosamil (Teflaro – Forest), an intravenous (IV) cephalosporin, for treatment of acute bacterial skin and skin structure infections, including those...
  • Botulinum Toxin for Chronic Migraine
    The FDA has approved injection of onabotulinumtoxinA (Botox – Allergan) for prevention of headaches in adult patients with chronic migraine (≥15 headache days/month for ≥3 months)....
  • In Brief: Denosumab for Bone Metastases
    The FDA, which recently approved subcutaneous (SC) administration of denosumab (Prolia – Amgen) for treatment of postmenopausal osteoporosis,1 has now approved the same drug with a...
February 7, 2011 (Issue 1357)  
  • In Brief: Benzonatate Warning
    The FDA recently warned that accidental ingestion of the antitussive benzonatate (Tessalon Perles, and others) by children less than 10 years old can be fatal.1 This widely prescribed oral...
  • Pegloticase (Krystexxa) for Treatment of Refractory Gout
    Pegloticase (Krystexxa – Savient), a PEGylated urate oxidase enzyme, has been approved by the FDA for intravenous (IV) treatment of chronic symptomatic gout in adults who have not...
  • Another Extended-Release Alpha2-Agonist for ADHD
    The FDA has approved an extended-release formulation of clonidine hydrochloride (Kapvay– Shionogi) for treatment of attention-deficit/hyperactivity disorder (ADHD) in children 6-17 years...
  • In Brief: Pancreatic Enzyme Products
    Pancreatic enzyme products (PEPs) have been used for decades to improve digestion in patients with insufficient pancreatic enzyme production, such as those with cystic fibrosis. All porcine-derived...
February 21, 2011 (Issue 1358)  
March 7, 2011 (Issue 1359)  
  • In Brief: FDA Warning on Dronedarone (Multaq)
    The FDA and the manufacturer (Sanofi-Aventis) have warned healthcare professionals that use of dronedarone (Multaq), an analog of amiodarone (Cordarone, and others) approved in...
  • Sunscreens Revisited
    Superseded by The Medical Letter "Sunscreens" - Issue 1553, August 13, 2018Sunscreens are widely used now, but some questions remain about their effectiveness and safety.
  • Alcaftadine (Lastacaft) for Allergic Conjunctivitis
    Alcaftadine (Lastacaft – Allergan), an ophthalmic H1-antihistamine, has been approved by the FDA for prevention of itching associated with allergic conjunctivitis in patients > 2...
  • In Brief: HPV Vaccine for Boys?
    The FDA has approved a new indication for prevention of anal cancer and anal intraepithelial neoplasia in both sexes for the human papillomavirus (HPV) vaccine Gardasil (Merck). This...
March 21, 2011 (Issue 1360)  
April 4, 2011 (Issue 1361)  
  • In Brief: PPIs and Hypomagnesemia
    The FDA has warned that prolonged use of a proton pump inhibitor (PPI) can lead to hypomagnesemia.1 Normal serum concentrations of magnesium are 0.7-1.0 mmol/L. About 30 cases of severe...
  • Potassium Iodide for Thyroid Protection in a Nuclear Accident
    Even though it is unlikely that people living in the US will be at risk of significant radiation exposure from the nuclear accident in Japan, some readers have suggested a review of the use of...
  • Intravenous Acetaminophen (Ofirmev)
    The FDA has approved an intravenous (IV) formulation of acetaminophen (Ofirmev – Cadence) for use in patients ≥2 years old for management of pain either as monotherapy (mild to...
  • In Brief: Another Three-Drug Combination for Hypertension
    The FDA has approved aliskiren/amlodipine/hydrochlorothiazide (Amturnide) for treatment of hypertension, with no restrictions except that it should not be used for initial therapy. A...
April 18, 2011 (Issue 1362)  
May 2, 2011 (Issue 1363)  
  • Duloxetine (Cymbalta) for Chronic Musculoskeletal Pain
    Previously approved by the FDA for treatment of depression, general anxiety disorder, diabetic peripheral neuropathic pain and fibromyalgia, duloxetine (Cymbalta – Lilly) has now also been...
  • Tesamorelin (Egrifta) for HIV-Associated Lipodystrophy
    The FDA has approved tesamorelin (Egrifta – EMD Serono), an injectable synthetic analog of growth-hormone- releasing factor (GRF), for reduction of excess abdominal fat in patients with...
  • Continuous Glucose Monitoring
    A variety of continuous glucose monitoring (CGM) devices have been used in an effort to reduce the hypoglycemia and wide glucose excursions that complicate insulin treatment of diabetes. Since...
May 16, 2011 (Issue 1364)  
May 30, 2011 (Issue 1365)  
June 13, 2011 (Issue 1366)  
June 27, 2011 (Issue 1367)  
July 11, 2011 (Issue 1368)  
July 25, 2011 (Issue 1369)  
August 8, 2011 (Issue 1370)  
August 22, 2011 (Issue 1371)  
September 5, 2011 (Issue 1372)  
  • Ticagrelor (Brilinta) - Better than Clopidogrel (Plavix)?
    The FDA has approved ticagrelor (Brilinta – AstraZeneca), an oral antiplatelet drug, for use with low-dose aspirin to reduce the rate of thrombotic cardiovascular events in patients with...
  • Gabapentin Enacarbil (Horizant) for Restless Legs Syndrome
    Gabapentin enacarbil (Horizant – GlaxoSmithKline), a new extended-release (ER) tablet formulation of gabapentin, has been approved by the FDA for treatment of moderate-to-severe restless...
  • Screening for Melanoma
    In the absence of randomized studies demonstrating an impact on mortality, the US Preventive Services Task Force (USPSTF) has found the evidence insufficient to recommend a routine whole-body...
September 19, 2011 (Issue 1373)  
October 3, 2011 (Issue 1374)  
October 17, 2011 (Issue 1375)  
  • Influenza Vaccine for 2011-2012
    Superseded by The Medical Letter "Influenza Vaccine for 2018-2019" - Issue 1558, October 22, 2018Annual vaccination against influenza A and B viruses is the most effective method of...
  • Do Calcium Supplements Increase the Risk of Myocardial Infarction?
    Supplemental calcium is recommended for prevention of postmenopausal osteoporosis in women with an inadequate dietary intake of calcium. The safety of calcium supplements has recently been...
  • In Brief: Propofol Revisited
    A reader has asked us to review the use of propofol (Diprivan, and others) as a sedative agent for brief procedures, such as colonoscopy.First marketed more than 20 years ago,1 propofol has...
October 31, 2011 (Issue 1376)  
November 14, 2011 (Issue 1377)  
November 28, 2011 (Issue 1378)  
  • What about Niacin?
    The results of the AIM-HIGH trial conducted by the US National Heart, Lung and Blood Institute (NHLBI) were recently published. The goal of the trial was to test whether addition of niacin to...
  • Once-Daily Gabapentin (Gralise) for Postherpetic Neuralgia
    A new once-daily formulation of gabapentin (Gralise – Depomed) has been approved by the FDA for treatment of postherpetic neuralgia (PHN). Immediate-release (IR) gabapentin...
  • Vaccines and Pregnancy
    Live-attenuated vaccines are generally contraindicated during pregnancy; inactivated vaccines can be given if indicated. A more detailed review of routine immunizations for adults will be...
  • In Brief: Icatibant (Firazyr) for Hereditary Angioedema
    The FDA has approved icatibant (Firazyr – Shire), a selective bradykinin B2 receptor antagonist, for treatment of acute attacks of hereditary angioedema (HAE). HAE is a rare autosomal...
December 12, 2011 (Issue 1379)  
  • Rivaroxaban (Xarelto) for Acute Coronary Syndrome
    The standard antithrombotic therapy for treatment of patients with acute coronary syndrome (ACS) is dual antiplatelet therapy with aspirin and clopidogrel (Plavix) or another...
  • Bleeding with Dabigatran (Pradaxa)
    The labeling of dabigatran etexilate (Pradaxa – Boehringer Ingelheim), an oral direct thrombin inhibitor, has recently been updated to include new dosing and monitoring recommendations...
  • Belatacept (Nulojix) for Prevention of Renal Transplant Rejection
    The FDA has approved belatacept (bel at´ a sept; Nulojix – Bristol-Myers Squibb) for prevention of organ rejection in adult patients receiving a kidney transplant.
  • Fentanyl Nasal Spray (Lazanda) for Pain
    The FDA has approved a nasal spray formulation of fentanyl (Lazanda – Archimedes) for management of breakthrough pain in adult cancer patients who are already receiving and are tolerant...
  • Who Should Take Vitamin Supplements?
    Many patients ask their healthcare providers whether they should take vitamins. Since the last Medical Letter article on this subject, more data have become available on the benefits and risks of...
  • Safety of Dronedarone (Multaq)
    Dronedarone (Multaq – Sanofi), an analog of amiodarone, was approved by the FDA in 2009 for oral treatment of paroxysmal or persistent (non-permanent) atrial fibrillation or atrial...
  • In Brief: Xigris Withdrawn
    The FDA has announced that Eli Lilly has voluntarily withdrawn drotrecogin alfa (activated) (Xigris) after a recently completed trial (PROWESS-SHOCK) in patients with severe sepsis and...
  • 2011 Annual Index (Online Only)
    View the 2011 Annual Index